Skip to main content
. Author manuscript; available in PMC: 2013 May 4.
Published in final edited form as: Expert Opin Ther Targets. 2010 Feb;14(2):143–155. doi: 10.1517/14728220903540257

Figure 2.

Figure 2

Molecular and pharmacological characteristics of KCa3.1, KCa2.X, and KCa1.1 channels. A: Activators of KCa3.1 and KCa2.1–3 channels. B: Openers of the KCa1.1 channel. Molar concentrations above structures are the reported EC50s. 1-EBIO, 1-ethyl-2-benzimidazolinone; BMS-204352, ([3S]-[+]-[5-chloro-2-methoxyphenyl]-1,3-dihydro-3-fluoro-6-[trifluoromethyl]-2H-indol-2-one); CyPPA, cyclohexyl-[2-(3,5-dimethyl-pyrazol-1-yl)-6-methyl-pyrimidin-4-yl]-amine; DC-EBIO, 5,6-dichloro-1-ethyl-1,3-dihydro-2H-benzimidazole-2-one; DHS-1, dehydrosoyasaponin-1; NS11021 1-(3,5-bis-trifluoromethyl-phenyl)-3-[4-bromo-2-(1H-tetrazol-5-yl)-phenyl]-thiourea; NS1608 (N-(3-trifluoromethyl)phenyl) N′-(2-hydroxy-5-chlorophenyl) urea; NS1619, 1,3-dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one; NS309, 3-oxime-6,7-dichloro-1H-indole-2,3-dione; SKA-31, naphtho[1,2-d]thiazol-2-amine.